Stryker Co. (NYSE:SYK) Shares Bought by Atria Investments Inc

Atria Investments Inc boosted its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 11.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 23,722 shares of the medical technology company's stock after purchasing an additional 2,383 shares during the quarter. Atria Investments Inc's holdings in Stryker were worth $8,570,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Tompkins Financial Corp lifted its stake in shares of Stryker by 1.3% in the 3rd quarter. Tompkins Financial Corp now owns 16,903 shares of the medical technology company's stock worth $6,106,000 after purchasing an additional 216 shares during the period. Bridges Investment Management Inc. boosted its position in shares of Stryker by 1.1% in the third quarter. Bridges Investment Management Inc. now owns 67,345 shares of the medical technology company's stock worth $24,329,000 after purchasing an additional 717 shares during the period. Klingman & Associates LLC boosted its position in shares of Stryker by 321.9% in the third quarter. Klingman & Associates LLC now owns 3,700 shares of the medical technology company's stock worth $1,337,000 after purchasing an additional 2,823 shares during the period. Assetmark Inc. increased its stake in Stryker by 30.7% in the 3rd quarter. Assetmark Inc. now owns 1,013 shares of the medical technology company's stock worth $366,000 after buying an additional 238 shares during the period. Finally, Verdence Capital Advisors LLC increased its stake in Stryker by 19.8% in the 3rd quarter. Verdence Capital Advisors LLC now owns 1,621 shares of the medical technology company's stock worth $586,000 after buying an additional 268 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 0.8 %

Shares of SYK traded up $2.90 during mid-day trading on Monday, reaching $378.86. The stock had a trading volume of 934,723 shares, compared to its average volume of 1,253,059. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 52-week low of $276.60 and a 52-week high of $381.54. The business's fifty day moving average is $361.46 and its 200 day moving average is $345.77. The firm has a market cap of $144.43 billion, a price-to-earnings ratio of 40.30, a P/E/G ratio of 2.83 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analysts' expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.46 earnings per share. On average, sell-side analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Insider Activity at Stryker

In related news, insider Viju Menon sold 600 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company's stock, valued at $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company's stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 67,381 shares of company stock valued at $24,825,275 over the last 90 days. 5.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SYK. Morgan Stanley increased their target price on shares of Stryker from $345.00 to $350.00 and gave the stock an "equal weight" rating in a report on Monday, July 15th. Stifel Nicolaus dropped their target price on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. BTIG Research increased their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Wells Fargo & Company increased their price objective on shares of Stryker from $381.00 to $405.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada lifted their price objective on shares of Stryker from $386.00 to $400.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.